| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6214865 | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jul, 2023
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6469182 | EISAI INC | Intermediates in the preparation of macrocyclic analogs |
Jun, 2019
(4 years ago) | |
| US7470720 | EISAI INC | Methods and compositions for use in treating cancer |
Jun, 2019
(4 years ago) | |
| US8097648 | EISAI INC | Methods and compositions for use in treating cancer |
Jan, 2021
(3 years ago) | |
|
US6214865 (Pediatric) | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jan, 2024
(3 months ago) | |
| USRE46965 | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jan, 2027
(2 years from now) | |
|
USRE46965 (Pediatric) | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jul, 2027
(3 years from now) | |
Halaven is owned by Eisai Inc.
Halaven contains Eribulin Mesylate.
Halaven has a total of 7 drug patents out of which 5 drug patents have expired.
Expired drug patents of Halaven are:
- US6469182
- US7470720
- US8097648
- US6214865*PED
- US6214865
Halaven was authorised for market use on 15 November, 2010.
Halaven is available in solution;intravenous dosage forms.
Halaven can be used as treatment of patients with metastatic breast cancer.
Drug patent challenges can be filed against Halaven from 13 March, 2025.
The generics of Halaven are possible to be released after 08 July, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-280) | Sep 13, 2025 |
| Pediatric Exclusivity(PED) | Mar 13, 2026 |
| New Indication(I-721) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 28, 2023 |
| Orphan Drug Exclusivity(ODE-107) | Jan 28, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2015 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
NCE-1 date: 13 March, 2025
Market Authorisation Date: 15 November, 2010
Treatment: Treatment of patients with metastatic breast cancer
Dosage: SOLUTION;INTRAVENOUS
HALAVEN family patents
